European Network of Gynaecological Oncological Trial Groups (ENGOT)
GOG Foundation
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
ECOG 0-1
Histologically or cytologically confirmed diagnosis of endometrial cancer documented as TP53WT
Subjects with advanced or recurrent disease must have completed a single line of up to 6 cycles of taxane-platinum based chemo and achieved a CR or PR per RECIST V1.1
Adequate hematologic, hepatic and renal function (within 14 days)
You may not be if
Has any sarcomas or small-cell carcinomas with neuroendocrine differentiation
Prior immune therapy, cytokine therapy, or any investigational therapy (within 28 days)
Indwelling surgical drains
Grade 2 or higher QTc prolongation
History of major organ transplant
History of bleeding diathesis; major hemorrhage or intracranial hemorrhage (within 24 weeks)
Clareo Health | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
